November 2011 Issue - Table of Contents

• On-Conversation with Jeff Patton, MD, Chief Executive Officer Tennessee Oncology, Chief Medical Officer RainTree Oncology Services
• Regional Variances in European Pancreatic Cancer Treatment and the Influential Power of Clinical Trial Participation
• Consolidations Come with Concerns as NCI Cooperative Groups Restructure
• Baker's Dozen Attempting to Beat the Odds in Pancreatic Cancer
• Relating Value in Cancer Care to Cost and Outcome
• Oncologists' Perspectives on the Future of Biosimilars
• Spotlight on Cost of Cancer Care: Bendamustine

September 2011 Issue - Table of Contents

• Embracing Clinical Pathways as a Viable Financial Model
• Spotlight on Cost of Cancer Care: Pemetrexed
• EHRs–Finding the Balance Between Functionality and Mobility
• 340B Benefits Some, Not Others: Money Redirected Through Expansion
• Ten Trends Transforming the Business of Oncology

July 2011 Issue - Table of Contents

• Building the Future of Cancer Care: Taking Multidisciplinary Care to a New Level
• What's in Store at ASCO 2011? Kantar Health Offers a Preview
• Drug Shortages Continue, Solutions are Evolving
• Preference for Oral Cancer Agents on the Rise
• OBR daily Editorial Commentary by Academic and Community Oncologists
• Spotlight on Cost of Cancer Care: Docetaxel

May 2011 Issue - Table of Contents

• Building the Future of Cancer Care: Taking Multidisciplinary Care to a New Level
• What's in Store at ASCO 2011? Kantar Health Offers a Preview
• Drug Shortages Continue, Solutions are Evolving
• Preference for Oral Cancer Agents on the Rise
• OBR daily Editorial Commentary by Academic and Community Oncologists
• Spotlight on Cost of Cancer Care: Docetaxel

March 2011 Issue - Table of Contents

• Payer Trends: Assisting with End of Life Discussions
• Regulating Molecular and Genetic Tests: NCCN Annual Meeting Coverage
• Epigenetics: Moving Beyond the Early Promise
• From Limbaugh, to ODAC, to FDA and Compendia, the Avastin Debate Continues (at least until June)
• Healthcare Reform: A Bitter Pill for Oncology?

January 2011 Issue - Table of Contents

• 2011 Forecast: Experts Provide Perspective on the Coming Year in Oncology
• '10 in Review
• 2013: Five Predictions for the Future of Oncology
• Oncology Market Adoption Trends: Quick Poll Results From ASH & SABCS
• The Oncology Professional Services Agreement
• Seeking an Oncology-Specific Accountable Care Model
• The 3rd Annual Outlook on the Pharmaceutical Promotional Landscape Within Oncology
• [view issue]

November 2010 Issue - Table of Contents:

• Conference Coverage: Highlights from the 2010 Cancer Center Business Summit
• U.K. & U.S. Cost & Comparative Effectiveness Policies Converge
• Past Pitfalls and Potential Promise for Pancreatic Cancer
• Healthcare Reform - Oncology Pap Program Design in the Age of the Federally Insured
• Spotlight on Cost of Cancer Care
• [view issue]

September 2010 Issue - Table of Contents:

• The Rise (and Fall?) of Avastin for the Treatment of Advanced Metastatic Breast Cancer
• Implementation of Clinical Pathways: Payers to Share Savings With Pathway Compliant Groups
• The FDA and Laboratory Developed Tests: The Brouhaha Continues
• Cancer Stem-like Cells: The Evolution of a Cancer Theory
• Prior Authorization - Preventing Waste or Waste of Time?
• [view issue]

July 2010 Issue - Table of Contents:

• The EMR Landscape: A Review of the ASCO 2010 EHR Lab
• Taking It Personal - When to Add Biomarkers to Treatment Guidelines
• Factors Driving the Current and Future Use of Oncology Biomarkers
• Innovative Advancements in Treating Cancer: Beyond Targeted Therapies
• ASCO 2010 Top News Stories
• Payer Reactions to Highly Anticipated Clinical Trial Presentations
• [view issue]

May 2010 Issue - Table of Contents:

• NCCN: Clinical and Economic Issues Impacting Cancer Care Delivery
• Payers Must Create Defensible Oncology Management Strategies
• Expansion of Section 340B Raises New Questions for Cancer Stakeholders
• Models and Mechanisms for Assiting the Underinsured
• Forecasting Success: the Misperceived Influence of FDA Approval
• Onconversation with James Sabry, MD, PhD, Vice President, Genentech Partnering
• [view issue]

March 2010 Issue - Table of Contents:

• The Ongoing Hopes and Challenges of Cancer Vaccines
• Managing the Health of Your Patients and Practice
• Risk-Sharing Schemes in Oncology - Future or Fad?
• A Perspective on Cancer Drug Pricing and Volume
• OBR Radar: Keeping an Eye on Projected Market Moving Events in the Oncology Pipeline
• [view issue]

January 2010 Issue - Table of Contents:

• Collaborative Efforts Speed Outcomes in Cancer Clinical Trials
• 2010 Forecast: Experts Provide Perspective on the Coming Year in Oncology
• The Ongoing Hopes and Challenges of Cancer Vaccines
• A Year-End Look at the Promotional Landscape Within Oncology
• [view issue]

November 2009 Issue - Table of Contents:

• Commercialization of Oncology Medicines and Federal Policy: Why Technology Transfer Offices Should Increase Their Activities on Coverage and Reimbursement Issues
• An Insider's Guide to Using Oncology-Specific EMRs
• Oncology-Specific EMRs Gain Traction: Suppliers Weigh In
• On-Conversation with Kenneth H. Buetow, PhD
• Attaining Breast Center Accreditation: Merging Market Share Goals with Quality Measures
• Panel Advises on Clinical Pathways: What, Why, and How
• [view issue]

September 2009 Issue - Table of Contents:

• Defining Meaningful Use Criteria for Electronic Health Records: An Early Adopter's Wish List
• The Increasing Incidence of Special Protocol Assessments
• Compliance Programs Partner in the Management of Oral Cancer Therapies
• Battling the High Cost of Nonadherence with Oral Cancer Therapies
• Oncologists: Cost-Effectiveness Policy Necessary Despite Quality of Care Warnings
• [view issue]

July 2009 Issue - Table of Contents:

• The Debate Over Episode-Based Payments in Oncology - Can This System Replace Buy and Bill?
• ACCME Regulation Takes Affect - Changing the CME Industry For Better or For Worse
• Select Biomarkers Possibly Ready for Prime Time: EGFR, HER2, and K-ras
• Economy Forcing Oncology Groups to Adjust Business Practices
• ERA-Based Data and Oncology Products: An Opportunity for Practices to Maximize Cash Flow
• [view issue]